For instance, the LDH-A inhibitor FX-11 (BGB-A1217) is being evaluated in clinical trials for its safety and efficacy in patients with solid tumors, with the expectation that it will enhance the activity of immune cells and increase the response rate to immunotherapy by reducing lactate levels in the tumor microenvironment (114). Here, LDHA is linked to neoplasm.